In order to speed up FDA review of novel drugs, Makary may need to stand up for user fees from pharmaceutical companies, which Health and Human Services Secretary Robert F. Kennedy, Jr., has previously criticized as potential conflicts of interest.
The U.S. Senate last week confirmed former Johns Hopkins surgeon and professor Dr. Marty Makary to lead the Food and Drug Administration.
During his confirmation hearing, Makary said his goals for the agency were “more cures and meaningful treatments for Americans.” Throughout the hearing, he offered insight on how he would achieve those goals, including leveraging artificial intelligence and making other regulatory changes to streamline the drug review process.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Here’s How Trump’s Pick To Lead The FDA Can Supercharge The Agency
Sally C. Pipes
In order to speed up FDA review of novel drugs, Makary may need to stand up for user fees from pharmaceutical companies, which Health and Human Services Secretary Robert F. Kennedy, Jr., has previously criticized as potential conflicts of interest.
The U.S. Senate last week confirmed former Johns Hopkins surgeon and professor Dr. Marty Makary to lead the Food and Drug Administration.
During his confirmation hearing, Makary said his goals for the agency were “more cures and meaningful treatments for Americans.” Throughout the hearing, he offered insight on how he would achieve those goals, including leveraging artificial intelligence and making other regulatory changes to streamline the drug review process.
That’s great news for patients.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.